chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Received vaccine Flu to (L) deltoid muscle on 10/6/10 states she has had pain 6/10 continues since date of injection. Denies applying any cold or hot compresses to arm. No swelling, no redness on Left arm. She is able to perform all ADL's without difficulty. Date reported 11/30/10.
Client was given Pfizer vaccine as a booster dose. His first 2 Covid Vaccines were Moderna.
Vaccine was not diluted. Full strength dose administered. No treatment or adverse s/s noted.
Subsequent post vax laboratory evaluation revealed failure to seroconvert following 2 dose of vax.
I start feeling body ache. So, I went to bed. As the night went on and, on the pain, got worst. I have a serve headache. My skin hurt; I could not put a blanket on. I had to the bathroom I could not walk, I felt like I was going to faint. I felt nausea. Went back to bed and started shaking. I was confused and did not know where I was. My skin also felt hot to the touch.
pain during injection/ arm pain/ hurts to sleep on that side at night; tiredness; nerve pain in arm muscle where she received the injection/ nerve and muscle pain in arm; nerve pain in arm muscle where she received the injection/ nerve and muscle pain in arm; decreased mobility of arm; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 61-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (about 5 years ago) and nerve pain (due to shingles infection).   On 8th June 2019, the patient received the 1st dose of Shingrix (intramuscular). On 8th June 2019, immediately after receiving Shingrix, the patient experienced injection site pain. In June 2019, the patient experienced tiredness, nerve pain, muscle pain and injected limb mobility decreased. On an unknown date, the outcome of the injection site pain and tiredness were recovered/resolved and the outcome of the nerve pain, muscle pain and injected limb mobility decreased were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain, tiredness, nerve pain, muscle pain and injected limb mobility decreased to be related to Shingrix.  Additional details were provided as follows: The patient reported for herself. The patient received Shingrix in left arm. During the injection, the patient felt pain. Less than a week after the shot, the patient felt tired and that resolved. About one week later, she developed nerve pain in her arm muscle where she received the injection. Since then, this muscle or nerve pain had persisted and she had decreased mobility of the arm and it hurt to sleep on that side at night. The patient did not consent to follow-up. This case has been linked to US2019168255, reported by the same reporter.
5 days p/vax temp fluctuations today t103, p/bath 102 now 430PM temp elevated to 105;loose stools, smelly, 2x day last 2 days;
not feeling that great.; arm more sore than the flu shot; fever; chills; This spontaneous case was reported by a consumer and describes the occurrence of MALAISE (not feeling that great.), PAIN IN EXTREMITY (arm more sore than the flu shot), PYREXIA (fever) and CHILLS (chills) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 015M20A) for COVID-19 vaccination.     Concurrent medical conditions included Hypertension and Thyroid disorder NOS. Concomitant products included LISINOPRIL for Hypertension.    On 10-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, the patient experienced MALAISE (not feeling that great.), PAIN IN EXTREMITY (arm more sore than the flu shot), PYREXIA (fever) and CHILLS (chills). At the time of the report, MALAISE (not feeling that great.), PAIN IN EXTREMITY (arm more sore than the flu shot), PYREXIA (fever) and CHILLS (chills) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication included were water pill and thyroid medication. Treatment details were not reported by the reporter.   This case was linked to MOD21-027949 (E2B Linked Report).; Sender's Comments:  MOD21-027949:
Patient developed arm redness which became cellulitis and had to have treatment with an antibiotic.
Patient came for Shingrix vaccine. Injected into the left arm deltoid site half way but syringe couldn't push in.  Re-vaccinated at the right arm deltoid site. Later at night, patient's left arm felt extremely painful, patient couldn't move or lift the whole arm from fingers to neck, just like "it's paralyzed" according to patient.  She couldn't move her fingers as well.
Very shortly after getting the vaccine the patient was in the post-vaccine waiting area and had a seizure that lasted about 30 seconds to 1 minute. EMS was called and patient was still very disoriented when EMS arrived and took him.
Information was received from a pharmacist regarding a 73 year old female who developed an injection site reaction following a vaccination with PNEUMOVAX 0.5 ml intramuscularly in her left arm on 18SEP2012. The pharmacist reported the patient received AFLURIA concomitantly in the same arm (separate sites, separated by about two inches). On 19SEP2012 the patient had an injection site reaction at the site of the PNEUMOVAX 23 described as a red, swollen, warm to touch, softball sized area (slightly irregular in shape). At the time of this report, the patient had not recovered. The pharmacist reported that the patient had received a previous vaccination with PNEUMOVAX 23 (date of previous vaccination unspecified some time prior to the patient's 65th birthday), without any reported problem. The pharmacist reported that the patient had received influenza vaccine (dates and manufacture unspecified) in previous years without problems. No other information was reported. Additional information has been requested.
ACUTE PULMONARY EMBOLISM HYPOXIA ALLERGIC REACTION, INIT
Food allergy to milk, which led to soy allergy, sorghum flour allergy  MERCURY IN THE VACCINE!
Palpitations. Tingling of lips.  Presented to ED. Observed x 4 hours. Patient improved. Discharged to PCP if sxs worsen. ED notes incomplete.
Patient called in complaining of left calf muscle cramping/ache. Told we would report to VAERS and for her to contact her primary care physician. She stated it started hurting on 4/14/21 upon awakening and it has continued to hurt as of 4/15/21.
Initial shot a couple of years ago / due to various things including the pandemic / unable to get the second shot; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose two years ago, from the day of reporting).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The case was reported by the patient. The age at vaccination was not applicable for this report. The patient had the initial shot a couple of years ago but, due to various things including the pandemic, he or she was unable to get the second shot.  Till the time of reporting, the patient did not receive the 2nd dose of Shingrix as per the vaccination schedule, which led to incomplete course of vaccination. The patient was quite sure it was Shingrix vaccine but did not know for sure. The reporter was asking if they should start over and get two shots or just get the second shot. The follow-up would not possible as no contact details were available. The case had been linked with the case- US2021AMR145801, reported by the same reporter.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR145801:Same reporter. Master case for "We"
Patient experienced soreness at injection site, high fever (102 for 3 days), severe headache, muscle pain, nausea and vomiting, stomachache, extreme fatigue, palor.  All these symptoms persisted for approximately 7 days.  On the 8th day, patient developed strep throat as diagnosed by his physician and was given antibiotics.
Narrative: unknown cause of death or if associated with vaccine 1st vaccine: 1/27/2021 2nd vaccine 2/25/21 death 2/27/2021 PMH: COPD Schizoaffective disorder prediabetes tremor + FIT UTI with hematuria right hip pain Reporting due to the proximity of vaccine administration in relation to death
Information has been received from a physician referring to an unspecified number of patients of unknown age and gender. The patients' concurrent conditions and medical history were not reported. On unknown dates, the patients were vaccinated with improperly stored VARIVAX (Merck) (lot # K 011804, expiration date 21-AUG-2016; lot # L021215, expiration date 10-JUN-2017, strength, dose and route were unknown). No adverse effects were reported. This is one of several reports received from the same reporter. Additional information has been requested.
On 12/06/2021, client requested to receive the Moderna booster. The Moderna booster, 0.25 ml, was administered. When entering the Covid-19 booster vaccination in the immunization record-sharing application, it was discovered the booster was given 72 days early. Booster was due 02/16/2022. Client was observed for 15 minutes following the injection.
Fever; This is a spontaneous report from a contactable consumer (the patient). An 82-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE, Lot number EN6203), via an unknown route of administration on 20Feb2021 (at the age of 82-years-old) as a single dose for Covid-19 immunization. Medical history included glaucoma from an unknown date. The patient previously received dose 1 of BNT162B2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE) on 30Jan2021. The patient's concomitant medications included timolol (MANUFACTURER UNKNOWN) and latanoprost (MANUFACTUER UNKNOWN), both from an unknown date for glaucoma. On 21Feb2021, the patient experienced fever and "all of the side effects is  listed on the website". Treatment for the fever included aspirin and a lot of water. The clinical outcome of the fever was unknown.
later in the day pt noted widespread pruritis then wednesday night she noted a rash at the trunk, arms, neck. the L upper deltoid, inferior to the injection site is erythematous, painful and itchy.
8 days after shot arm became itchy, red, swollen, and hot at the injection site.  Raised red area around injection site is approximately two inches from center in a circle.  Entire upper arm is sore and upper back through shoulder blade is sore also.   Took benadryl the night it presented and drew circle around red/raised area to determine if it spreads.   Took zyrtec the next morning and put ice on throughout the day.  The red raised area has spread some and it remains hot to the touch.   Also began having problems with asthma and used rescue inhaler more than usual.
This case was reported by a consumer via call center representative and described the occurrence of C-reactive protein increased in a 70-year-old male patient who received SHINGRIX for prophylaxis. The patient's past medical history included arthritis and rheumatoid arthritis (rheumatology issues with joint pain). In June 2018, the patient received the 1st dose of SHINGRIX. In June 2018, less than a month after receiving SHINGRIX, the patient experienced joint pain, tiredness, influenza-like symptoms, pain and pain in arm. On 18th September 2018, the patient experienced C-reactive protein increased and sedimentation rate increased. On an unknown date, the outcome of the C-reactive protein increased and sedimentation rate increased were not reported and the outcome of the joint pain was not recovered/not resolved and the outcome of the tiredness, influenza-like symptoms, pain and pain in arm were recovered/resolved. It was unknown if the reporter considered the C-reactive protein increased, joint pain, tiredness, influenza-like symptoms, pain, sedimentation rate increased and pain in arm to be related to SHINGRIX. Additional details were reported as follows: This case was not previously reported to anyone. Specific vaccination date was unknown. The patient experienced arm soreness, flu like symptoms consisting of achiness all over and tiredness. On 18th September 2018, the patient had routine blood work done and it was discovered that he had a high C-Reactive Protein count and his sedimentation rate was high. The patient reported joint pain that would not resolve. The contact details of the physician was provided. This case was linked with case US2018177087, reported by same reporter.
missed 2nd vaccine window; This spontaneous case was reported by a consumer and describes the occurrence of PRODUCT DOSE OMISSION ISSUE (missed 2nd vaccine window) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history were reported. .     On 15-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (missed 2nd vaccine window). At the time of the report, PRODUCT DOSE OMISSION ISSUE (missed 2nd vaccine window) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant and  treatment medications were provided. No lab data has been provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 13-Jul-2021: TCR: nonsafety info
Redness, soreness, swelling and itching at site of injection.  Low grade fever.  Took Tylenol.
I started with an itchy face. Then it turned into hives, swelling, a fever, chills, and muscle cramps. My face is now covered in scabs and infected, and swollen. Tender to the touch, and stings very much.
Pain, redness, swelling in arm; can't lift arm. Went to doctor; received antibiotics to ward off abscess formation.
pain in his right hip and shoulder.; This is a spontaneous report from a Pfizer-sponsored program. A contactable consumer (patient's wife) reported for male patient(husband) of an unknown age received first dose of BNT162B2 (Pfizer-Biontech COVID-19 Vaccine, Solution for injection, batch/lot number: unknown), via an unknown route of administration in left arm on 16Feb2021 for COVID-19 immunisation. The patient medical history and concomitant medications were not reported. On an unknown date, the patient experienced pain in his right hip and shoulder. It was reported that No patient identifiers were provided but the reporter has firsthand knowledge of the patient and was reporting on a specific patient. Both caller and her husband got their 1st doses on Tuesday. The patient's HCP scheduled him out 4 weeks instead of 3. The outcome of the events was unknown.  Information on the lot/batch number has been requested. Follow-up attempts were completed. No further information was expected.
Patient's throat got itchy immediately after vaccine was administered. Benadryl 50mg was given. About 7 minutes after vaccine was given patient flushed red and started complaining of chest tightness followed by swelling in her mouth and throat. Epipen 0.3mg was administered and 911 called. Patient's breathing returned to normal before EMS got there. Patient was taken to the hospital by EMS.
the psoriasis returned; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP), Program ID: The reporter is the patient. A patient (no qualifiers provided) received BNT162b2 (BNT162B2), in Oct2021 as dose 3 (booster), single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, MANUFACTURER UNKNOWN), for covid-19 immunization; Bnt162b2 (DOSE 2, SINGLE, MANUFACTURER UNKNOWN, after my second shot in Apr2021, my psoriasis cleared right up! It lasted through my first booster I received in Oct2021. In May2022, the psoriasis returned.), administration date: Apr2021, for covid-19 immunization, reaction(s): "psoriasis". The following information was reported: PSORIASIS (non-serious) with onset May2022, outcome "unknown", described as "the psoriasis returned". Additional information: Patient just wanted to let all know about an exciting side effect the patient had from shots: after patient's second shot in Apr2021, psoriasis cleared right up. It lasted through first booster patient received in Oct2021. In May2022, the psoriasis returned. Patient just got second booster yesterday and was hoping for the same psoriasis remission. Obviously, the shot was boosting patient's immune system. Seems like this was something that would be of great help to psoriasis suffers.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Information has been received from a nurse concerning a 6 yr old male who on 31Mar00 was vaccinated with a dose of varicella virus vaccine live (lot631076/0453J). On 22Feb06 the pt experienced shingles characterized by a T2 dermatomal rash. Unspecified medical attention was sought and the pt was treated with acyclovir. No outcome information was reported. No product quality complaint was involved. The reporter considered the pt's adverse experience to be an other important medical event (OMIC). Additional information has been requested.
Insomnia; Dose 1: 17Apr2021 and Dose 2: 02May2021; This is a spontaneous report from a contactable consumer, the patient. A 45-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0161) via an unspecified route of administration in the left arm on 02May2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medication. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 17Apr2021 at 12:00 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. On 02May2021 at 16:00, the patient experienced insomnia. The event insomnia did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event insomnia was not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
I was in my first trimester of pregnancy when I received my first dose. My due date was date. I ended up having a pre-term baby at 36 weeks, 5 days on earlier date and my baby was small for gestational age, weighing only 4 lbs, 8 ounces at birth. I also was diagnosed with pre-eclampsia in my last month of pregnancy. I did not have an adverse reaction immediately following my vaccine, but wanted to note my pregnancy complications in case they were related.
Aches and pains similar to a fever night of vaccine.  Injection site is mildly swollen and redness about 2-3 inches in diameter
Patient received a Pfizer booster dose (LOT# FJ6369). At 1344 reported feeling nauseous, sweaty, and slightly dizzy to vaccinator EMT. RN 1 and EMT assisted patient into anti-gravity chair. At 1345, RN 1 assessed patient: 120/80 blood pressure; pulse rate 103 beats/minute; and 98% SpO2. Patient denied itchiness, rashes, difficulty swallowing or difficulty breathing. Patient given juice. Patient drank juice. Patient reported history of similar reaction to second dose of Pfizer. Patient reported history of generalized anxiety disorder and feeling nervous before appointment. Patient takes Prozac and has no known allergies. At 1357, RN 1 reassessed patient: 122/88 blood pressure; pulse rate 95 beats/minute; and 98% SpO2. Patient denied feeling nauseous and dizzy. Patient reported history of reaction to his second dose of Pfizer. Patient reported indigestion and left sided chest pain radiating to shoulder and lower back. Patient reported seeking urgent care and no follow up with PCP. Patient reported he did not reported second dose reaction to vaccinator before vaccination. At 1410, RN 1 reassessed patient: 140/100 blood pressure; pulse rate 92 beats/min (irregular); and SpO2 97%.  At 1414, RN 1 reassessed patient: 152/100 blood pressure; pulse rate 90 beats/minute (irregular); and SpO2 97%. RN 1 reported irregular pulse and patient history to RN 2. RN 1 offered EMS to patient. At 1430, RN 1 activated EMS. At approximately 1437, paramedics arrived on scene and assumed care. At 1443, paramedics left facility and transferred patient to another HCF.
07/10/22 presents to ED for "altered mental status". PMHx of "ADHD"
Ongoing constipation since receiving the vaccine (with no changes in diet, water intake, etc. since before/after receiving the vaccine)
Pt stated trouble breath after 5 hours of having flu vaccine IM. Pt stated allergies to lactose & nuts. Pt states dizzy, blurred vision. Pt voice hoarse, taken across the street Medical Center by personnel and nurse.
V ARlV AX was administered to his 19 year old son today 1/5/2020 at 12: 15 PM via intramuscular route; No additional AE; This spontaneous report was received from a physician reporting for his son and refers to a 19-year-old male patient. His concurrent conditions included allergy to diary products. His concomitant therapies and previous drug reactions were unknown.  On 05-JAN-2021 at 12:15, the patient was vaccinated with varicella virus vaccine live (oka/merck) (VARIVAX) via intramuscular route (strength, dose, lot #  and expiration date were not provided) as a booster of varicella virus vaccine live (oka/merck) (VARIVAX) based on titer levels. The vaccine was administered in an inappropriate route as it should have been administered subcutaneously. There was no treatment given for the event. There were no additional adverse events (AE) reported. No further information was provided. The outcome of the event was not reported.
This spontaneous report was received from a nurse and refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions, concomitant therapies or medical history provided. On unknown date, the patient was vaccinated with improperly stored doses ZOSTAVAX lot # M019645, expiration date 18-JUL-2017 (exact dose and route of administration were not reported). No adverse effects were reported. Administered dose of the vaccine experienced the temperature excursion of -7.1 degrees Celsius (C) for 2 hours 2 minutes on 10-AUG-2016 and -8.1 C for 1 hour 14 minutes on 25-AUG-2016 (cumulative: maximum -7.1 C for 3 hours 16 minutes). There was no prior excursions. Data logger was involved. This is one of several reports received from the same reporter. Additional information has been requested.
I have a rash under the shot, and my arm still hurts.  I got the shot on Fri. the 25th of Sept.
Case number PHEH2014US020124 is an initial spontaneous report from the nurse on 06 Oct 2014. This report refers to a 16-year-old female patient. She was inadvertently vaccinated with only Men CYW-135 liquid component of MENVEO (batch number: A14044) intramuscularly without reconstitution with Men A lyophilized component on 25 Aug 2014. No adverse event reported following this medication error.
Dizziness, Headache, Myalgia, Fever, FATIGUE, LOSS OF TIME Narrative: